SCHEMBL1286996

SCHEMBL1286996

COC(=O)c1ccnc(CN2C(C)(C)CCCC2(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 4/20 0.44
▸ KDM5C P41229 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ KDM6B O15054 1/20 0.44
▸ KDM2A Q9Y2K7 1/20 0.44
▸ KDM3A Q9Y4C1 1/20 0.44
▸ JMJD6 Q6NYC1 1/20 0.42
▸ ALOX15 P16050 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KDM5B Q9UGL1 6/20 0.41
▸ KDM5A P29375 5/20 0.41
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HTT P42858 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ OPRD1 P41143 1/20 0.37
▸ HIF1A Q16665 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9736097 0.79 KDM4C (0.54) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL1287029 0.75 KDM4C (0.44) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL1287113 0.73 NPC1 (0.45) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL1287025 0.73 KDM5C (0.51) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL348975 0.73 KDM4C (0.57) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL31320065 0.73 KDM4E (0.57) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL30740808 0.73 KDM4C (0.57) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL10263738 0.73 KDM4E (0.57) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL29700409 0.72 KDM4E (0.55) KDM4CKDM5CKDM4EKDM6BKDM2A
SCHEMBL22005801 0.72 KDM5C (0.55) KDM4CKDM5CKDM4EKDM6BKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012047156-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS PLASMINOGEN INHIBITORS AND THEIR USE IN THE TREATMENT OF FIBRINOLYSIS RELATED DISEASES ASTRAZENECA AB (SE) 2012-04-12 — — WO disclosed
Send feedback